A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas
Latest Information Update: 10 Mar 2025
At a glance
- Drugs LCB 71 (Primary)
- Indications Advanced breast cancer; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors CStone Pharmaceuticals
Most Recent Events
- 05 Mar 2025 According to a CStone Pharmaceuticals media release, company announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL
- 19 Dec 2024 According to a CStone Pharmaceuticals media release, company announced that this study also holds the potential to evolve into a Phase 2 single-arm registrational trial for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- 19 Dec 2024 According to a CStone Pharmaceuticals media release, company announced the enrollment of the first patient in the global multicenter Phase 1b clinical trial of CS5001